Mystery San Diego party inks $300m deal with Abzena for antibody linking tech
An unnamed San Diego-based firm has signed a licensing agreement for Abzena Plc’s ThioBridge antibody drug conjugate (ADC) linker technology.
Archives for January 24, 2017
Entering the RAT race? FDA issues instructions for new cell therapy designation
Drugmakers have been invited to submit preliminary clinical evidence for cell and gene therapies under the new US FDA Regenerative Advanced Therapy designation
ADMA to buy US Biotest plant and fix problems that derailed RI-002
ADMA Biologics has agreed to buy production assets from the CMO whose manufacturing deficiencies saw the US FDA reject its lead candidate, RI-002, last year.